Showing results 1 to 2 of 2
Title | Author(s) | Issue Date | |
---|---|---|---|
LUX-breast 2: Phase II, open-label study of oral afatinib in HER2-overexpressing metastatic breast cancer (MBC) patients (pts) who progressed on prior trastuzumab (T) and/or lapatinib (L) Proceeding/Conference:Journal of Clinical Oncology | 2012 | ||
2021 |